Enforcement Trends: OIG Calls Out CMS for Not Preventing Medicare Genetic Testing Overpayments
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
From - National Intelligence Report
Although it's still a profitable endeavor, enforcing federal health care fraud laws isn't providing the investment returns of yesteryears…
From - National Intelligence Report
As a rule of thumb, FDA approvals are a snapshot applicable only to the product as it exists at the time of review and approval…
From - National Intelligence Report
Risk of federal prosecution for health fraud and abuse applies only when you deal with Medicare, TRICARE or other federal health programs…
From - National Intelligence Report
Fraudulent utilization and billing of urine drug screening first became a priority for federal enforcers since the…
From - National Intelligence Report
A new report from OIG details Medicare Fraud Control Unit (MCFU) enforcement activity in fiscal year…
From - National Intelligence Report
The opioid crackdown has made urine drug testing an even greater priority for federal health fraud enforcers. One principle target is specimen validity testing…